Designing GLP
The culmination of these scientific advancements provides valuable insights for the development of more effective treatments for metabolic disorders, ultimately paving the way for improved patient ...
This review advances the perspective that future GLP-1 therapeutics will be optimized through the integration of receptor pharmacology, formulation engineering, and precision clinical deployment.
FORMULATION DEVELOPMENT
SUMMARY Evaluation of drug delivery systems for GLP-1 receptor agonists from injectable to advanced oral, buccal, transdermal, and intranasal formulations has resulted in significant milestones in the treatment of obesity and type 2 diabetes.
Published in 2025, providing an up-to-date overview of GLP-1 delivery technology including the latest formulation advances.
Recent advances and trends in oral absorption enhancements of GLP
Background Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) offer significant clinical benefits in treating type 2 diabetes and obesity. However, owing to their peptide-based composition, GLP -1RAs have traditionally required injectable administration, which undermines patient adherence, convenience, and long-term accessibility. Recent advancements—including the approval of oral ...
The objectives of this study were twofold. First, we aimed to develop a state-of-the-art lipid-based formulation of a model GLP-1 analog, exenatide (EXE), which is formulated as a HIP and combined with a permeation enhancer to achieve a low-particle-size dispersion optimized for intestinal absorption.
Advances in GLP
Recent advances in drug delivery technologies, including nanocarrier- and microcarrier-based systems, hydrogels, microneedles, and innovative formulations such as long-acting, co- and/or nano-formulated agents, offer promising strategies to enhance the delivery, efficacy, and patient adherence of GLP -1RAs for obesity and diabetes.
Accordingly, formulation -based innovation is particularly critical for GLP-1 RAs. In recent years, nanotechnology-enabled drug delivery systems have gained increasing attention as a promising strategy to overcome the stability and delivery barriers associated with various drugs including peptide therapeutics [18 - 22].
Key Details About Advancement In Glp 1 Formulation
GLP-1 manufacturing challenges across peptide synthesis, formulation , and supply chain, and why oral small molecules like orforglipron could reset the economics of production.
Abstract Background Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) offer significant clinical benefits in treating type 2 diabetes and obesity. However, owing to their peptide-based composition, GLP -1RAs have traditionally required injectable administration, which undermines patient adherence, convenience, and long-term accessibility. Recent advancements — including the approval of oral ...